AutoRegenic Immunologics is a precision medicine research and development company that is productizing tissue regeneration treatments for immunodeficiency diseases—like sickle cell anemia and blood cancers—based on its manufacturing, specialization and formulation of “rebirthed” stem cells. Sickle cell disease affects millions of people of African origin worldwide, killing over 115,000 each year. Blood cancer attacks over 1.2 million people and claims around 700,000 lives per year. AutoRegenic cell manufacturing is a safe, ethical and affordable process that encompasses performing nuclear transfer to create naïve pluripotent stem cells that are differentiated on-demand into generous doses of youthful hematopoietic (blood-generating) stem cells to rebuild the immune system. The AutoRegenic biomedicine is both broad and precise, treating the source of the diseases, rather than their cascade of secondary effects. The ARI service aims to disrupt three critical challenges in treating immunodeficiency and blood diseases: (1) eliminating the need for blood donors; (2) using a smart registry and artificial intelligence to match the best biomedicines and allograft applications to patients; and (3) providing ample volumes of vital, personalized stem cell doses for patients.
Our team is comprised of experienced entrepreneurs from the biomedical, pharmaceutical, blood donor, technology, regulatory and marketing fields, supported by a world-class scientific advisory board, including international experts in the field of regenerative medicine and transplantation, and uniquely skilled laboratory technicians.
We are busy productizing an unique set of laboratory techniques, processes, materials, and international logistics for producing naive pluripotent stem cells that promise to become a safe, effective, practical, ethical and affordable innovation of blood stem cell sourcing and transplants on a patient-specific basis.
Following 13 years of applied R&D, seven of which led to a safe and successful pioneering autologous stem cell regeneration treatment of damaged section of the spine of a comprehensive quadriplegic male patient in November 2012 (whose condition markedly improved), a variation of the progenitor derivation process has enabled the production of autologous hematopoietic stem and progenitor cells (HSPCs) for blood transplant applications. An experimental case study utilizing these nuclear transfer-derived HSPCs is currently underway in South Africa.